JPM21: Gene editing for heart disease, a new date to watch in Alzheimer's and Pfizer's deep pockets
Share it The second day of the J.P. Morgan Healthcare Conference didn't bring any billion-dollar acquisitions or high-priced partnerships. But the light slate of news felt a little less existential than might be expected for a meeting that prides itself on market-moving developments. Biotech stock indices continue to do well, boosted by a stretch of dealmaking that closed out 2020. Venture and IPO fundraising hit record highs last year. And the industry is one month removed from the success of coronavirus vaccines developed by Moderna and partners Pfizer and BioNTech. While quiet, the 39th an...
Source: biopharmadive.com